Filing Flows › Travere Therapeutics (TVTX) › Q2 2026 › vs Q2 2025
Travere Therapeutics (TVTX) Q2 2026 vs Q2 2025 (year over year)
Travere Therapeutics's revenue rose $55.1M (+48%) from $114M in Q2 2025 to $170M in Q2 2026. The biggest changes: Total net product sales +$66.5M (+70%); License and collaboration revenue −$11.4M (-58%).
Travere Therapeutics, Q2 2026: revenue $170M (+48% year over year), operating margin 2.3%, net loss $34.8M, operating cash flow $58.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| FILSPARI | $141M | $71.9M | $69.2M | +96% |
| Tiopronin products | $20.3M | $23.0M | −$2.7M | -12% |
| Total net product sales | $161M | $94.8M | $66.5M | +70% |
| License and collaboration revenue | $8.2M | $19.6M | −$11.4M | -58% |
| Revenue | $170M | $114M | $55.1M | +48% |
| Income tax benefit | $204K | −$20K | $224K | — |
| Net loss | $34.8M | $12.8M | $22.0M | +173% |
| Costs & expenses | $205M | $127M | $77.4M | +61% |
| Operating costs | $166M | $127M | $38.5M | +30% |
| Interest & other, net | $39.0M | $85K | $38.9M | 458× |
| Cost of revenue | $2.2M | $1.5M | $653K | +43% |
| Research & development | $60.3M | $49.4M | $10.9M | +22% |
| SG&A | $96.1M | $62.6M | $33.5M | +54% |
| Other operating costs | $7.1M | $13.6M | −$6.6M | -48% |
| Operating cash sources | $92.9M | $17.7M | $75.1M | +424% |
| Depreciation & amortization | $4.2M | $14.0M | −$9.8M | -70% |
| Share-based compensation | $21.8M | $10.6M | $11.1M | +105% |
| Working capital & other | $66.8M | −$6.9M | $73.8M | — |
| Net loss absorbed | $34.8M | $12.8M | $22.0M | +173% |
| Operating cash flow | $58.1M | $5.0M | $53.1M | 12× |
Questions
How much did Travere Therapeutics's revenue grow year over year in Q2 2026?
Travere Therapeutics's revenue rose $55.1M (+48%) from $114M in Q2 2025 to $170M in Q2 2026.
What drove Travere Therapeutics's revenue change in Q2 2026?
Total net product sales +$66.5M (+70%); License and collaboration revenue −$11.4M (-58%).